GEN3017 / Genmab - LARVOL DELTA

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=9 | Terminated | Sponsor: Genmab | N=240 ➔ 9 | Trial completion date: Dec 2032 ➔ Feb 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2029 ➔ Feb 2025; Genmab discontinued GEN3017 program following a strategic re-evaluation of Genmab's portfolio.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=240 | Active, not recruiting | Sponsor: Genmab | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=240 | Recruiting | Sponsor: Genmab | Trial completion date: Jun 2028 ➔ Dec 2032

Trial completion date • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=240 | Recruiting | Sponsor: Genmab | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1/2 | N=240 | Not yet recruiting | Sponsor: Genmab

New P1/2 trial • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies (ASH 2022) - "In the last decade, treatment regimen including brentuximab vedotin have significantly improved prognosis for patients with CD30-expressing lymphomas...Here, we report preclinical data for the novel DuoBody®-CD3xCD30 (GEN3017), a CD3 bsAb targeting CD30-expressing tumor cells...CD30-expressing HL (L428) and ALCL (KI-JK) tumor cell lines were incubated with purified healthy donor T cells (E:T ratio = 4:1) and DuoBody-CD3xCD30 or bsIgG1-CD3xctrl for 72 hours. T-cell mediated cytotoxicity was measured by flow cytometry and expressed as the percentage viable tumor cells normalized to an untreated control sample."

Preclinical • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD4 • CD8 • TNFRSF8